On Tuesday, Compania de Minas Buenaventura SAA (ADR) (NYSE:BVN)’s shares declined -0.89% to $6.65.
The first bullet point in the Second Quarter 2015 Highlights should read: In 2Q15, EBITDA from direct operations was US$32.9 million and adjusted EBITDA (counting associated companies) was US$90.7 million. (instead of …adjusted EBITDA (counting associated companies) was US$92.4 million.)
BUENAVENTURA DECLARES SECOND QUARTER AND SIX-MONTH PERIOD 2015 RESULTS
Compañia de Minas Buenaventura S.A.A. (“Buenaventura” or “the Company”) (NYSE:BVN; Lima Stock Exchange:BUE.LM), Peru’s largest publicly-traded precious metals mining company, declared recently results for the second quarter (2Q15) and six-month (6M15) periods, ended June 30, 2015. All figures have been prepared in accordance with IFRS (International Financial Reporting Standards) on a non GAAP basis and are stated in U.S. dollars (US$).
Second Quarter 2015 Highlights:
- In 2Q15, EBITDA from direct operations was US$32.9 million and adjusted EBITDA (counting associated companies) was US$90.7 million.
- Total attributable production (counting associates) in 2Q15 was 186k gold ounces and 4.4 million silver ounces (contrast to 191k gold ounces and 4.6 million silver ounces in 2Q14).
- At the Tambomayo project, construction permits were granted in June 2015. Production should start in 3Q16 at 1,500 TPD (120K-150K gold ounces and 2.5-3.0 million silver ounces per year).
- At the San Gabriel (Chucapaca) project, construction of the ramp started in June 2015. The Environmental Impact Assessment (EIA) of the project´s construction is predictable to be presented in 3Q15.
Compañía de Minas Buenaventura S.A.A., a precious metals company, engages in the exploration, mining, and processing of gold, silver, lead, zinc, and copper metals in Peru. The company operates five directly operating mining units, counting Uchucchacua, Orcopampa, Julcani, Mallay, and Breapampa; and two mining unites that are under development stage comprising Tambomayo and San Gabriel.
BGC Partners, Inc. (NASDAQ:BGCP)’s shares dropped -0.20% to $9.88.
BGC Partners, Inc. (BGCP) a leading global brokerage company servicing the financial and real estate markets, and the Company’s majority-owned division, GFI Group Inc. (GFIG) (“GFI Group” or “GFI”), a leading intermediary and provider of trading technologies and support services to the global OTC and listed markets, stated financial results for the quarter ended June 30, 2015.
BGC Partners, Inc. operates as a brokerage company in the United Kingdom, the United States, and internationally. It operates in two segments, Financial Services and Real Estate Services. The Financial Services segment provides brokerage services, counting fixed income securities, interest rate swaps, foreign exchange, equities, equity derivatives, credit derivatives, commodities, futures, and structured products.
At the end of Tuesday’s trade, AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)‘s shares surged 9.88% to $4.45.
AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, recently offered a business update and stated financial results for the three and six months ended June 30, 2015.
Business highlights comprise:
- On July 23, 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Zalviso™ for the administration of acute moderate-to-severe post-operative pain in adult patients in a hospital setting. A decision by the European Commission (EC) on the approval of Zalviso is anticipated in late September or early October.
- AcelRx has been granted a General Advice meeting with the U.S. Food and Drug Administration (FDA) in early September to talk about the FDA’s request for a clinical trial and the company’s planned response to the Complete Response Letter (CRL) issued by the FDA for the New Drug Application (NDA) for Zalviso.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company’s lead product candidate is Zalviso, an investigational, pre-programmed, non-invasive, handheld system that has accomplished Phase III clinical trials for the treatment of moderate-to-severe acute pain in the hospital setting.
Campbell Soup Company (NYSE:CPB), ended its Tuesday’s trading session with -0.40% loss, and closed at $49.68.
Campbell Soup Company (CPB) offered an update on the company’s key planned imperatives. Led by President and Chief Executive Officer Denise Morrison, executives outlined important actions the company is taking to reshape Campbell and improve its growth trajectory by strengthening its core business and expanding into faster-growing spaces. This comprises Campbell’s plans to change many of its recipes, to build stronger connections with consumers and to enhance the company’s focus on faster-growing categories, such as health and well-being and developing markets.
Providing Consumers with Information on How Campbell’s Food Is Made
Morrison and Americas Simple Meals and Beverages President Mark Alexander outlined plans to assist consumers access a wide range of information about how Campbell’s foods and beverages are made and the choices behind ingredients, particularly in its core U.S. Soup, Sauces and Beverages portfolio. Campbell is making this information accessible on www.whatsinmyfood.com.
The site provides detail on several of Campbell’s top brands, such as iconic Campbell’sCondensed Tomato and Chicken Noodle soups, Slow Kettle Style and Healthy Request soups and Campbell’s Dinner Sauces. Over the next year, Campbell will expand its efforts to comprise all major brands in the U.S. and Canada, with plans to expand it globally over the next three years.
Campbell Soup Company, together with its auxiliaries, manufactures and markets convenience food products. It operates through U.S. Simple Meals; Global Baking and Snacking; International Simple Meals and Beverages; U.S. Beverages; and Bolthouse and Foodservice segments. The U.S. Simple Meals segment offers Campbells condensed and ready-to-serve soups; Swanson broth and stocks; Prego pasta sauces; Pace Mexican sauces; Campbells gravies, pasta, beans and dinner sauces; and Swanson canned poultry .
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
